K

Kaken Pharmaceutical Co Ltd
TSE:4521

Watchlist Manager
Kaken Pharmaceutical Co Ltd
TSE:4521
Watchlist
Price: 4 172 JPY -1.18% Market Closed
Market Cap: 158B JPY
Have any thoughts about
Kaken Pharmaceutical Co Ltd?
Write Note

Kaken Pharmaceutical Co Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Kaken Pharmaceutical Co Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
K
Kaken Pharmaceutical Co Ltd
TSE:4521
Total Current Assets
ÂĄ122.7B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
8%
Takeda Pharmaceutical Co Ltd
TSE:4502
Total Current Assets
ÂĄ3.1T
CAGR 3-Years
8%
CAGR 5-Years
5%
CAGR 10-Years
6%
Daiichi Sankyo Co Ltd
TSE:4568
Total Current Assets
ÂĄ1.9T
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
7%
Otsuka Holdings Co Ltd
TSE:4578
Total Current Assets
ÂĄ1.4T
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
2%
Chugai Pharmaceutical Co Ltd
TSE:4519
Total Current Assets
ÂĄ1.3T
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
10%
Astellas Pharma Inc
TSE:4503
Total Current Assets
ÂĄ1.2T
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
2%
No Stocks Found

Kaken Pharmaceutical Co Ltd
Glance View

Market Cap
158B JPY
Industry
Pharmaceuticals

Founded in 1948, Kaken Pharmaceutical Co., Ltd. is a prominent player in Japan's pharmaceutical landscape, seamlessly blending tradition with innovation. The company's journey began amidst post-war economic rebuilding, initially catering to the nation's healthcare needs with basic medicines. Over the years, it has carved out a niche for itself, specializing in the development, manufacturing, and commercialization of a wide range of pharmaceutical products. Kaken's focus areas include dermatology, orthopedics, and surgery, with a strong emphasis on treatments for fungal infections and inflammation management. This specialization has propelled the company into a position of leadership, especially in the dermatology market, where its expertise in topical formulations excels. Kaken Pharmaceutical monetizes its ventures primarily through the sale of prescription and over-the-counter drugs, leveraging a robust distribution network that extends its reach across Japan and international markets. The company continually reinvests in research and development to sustain its competitive edge, regularly introducing innovative therapies that address unmet medical needs. While pharmaceuticals remain its core revenue stream, Kaken also generates income from its chemical businesses, which include agrochemicals and animal health products, further diversifying its portfolio. By maintaining a balanced blend of traditional pharmaceutical sales and chemical product lines, Kaken ensures steady financial footing while advancing health solutions for a global audience.

Intrinsic Value
1 867.16 JPY
Overvaluation 55%
Intrinsic Value
Price
K

See Also

What is Kaken Pharmaceutical Co Ltd's Total Current Assets?
Total Current Assets
122.7B JPY

Based on the financial report for Sep 30, 2024, Kaken Pharmaceutical Co Ltd's Total Current Assets amounts to 122.7B JPY.

What is Kaken Pharmaceutical Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
8%

Over the last year, the Total Current Assets growth was 9%. The average annual Total Current Assets growth rates for Kaken Pharmaceutical Co Ltd have been 2% over the past three years , 4% over the past five years , and 8% over the past ten years .

Back to Top